Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002392 · ClinicalTrials.gov registry record · NA

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

A NA study of HIV Infections, sponsored by Rockefeller University.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT00002392 is a NA study of HIV Infections that has completed, run by Rockefeller University. The registered enrollment target is 12 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002392, a NA study of HIV Infections, has completed, sponsored by Rockefeller University.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and parameters of specific, anti-HIV cellular immunity.

Conditions Studied

HIV Infections

Interventions

  • DRUG Thalidomide

Study Locations (1)

New York

  • Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ - New York

Trial Details

FieldValue
Enrollment Target 12 participants
Phase NA

Sponsor

Rockefeller University

117 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00002392

The ClinicalTrials.gov registry entry for NCT00002392 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower). The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Thalidomide is the first listed.

NCT00002392 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00002392 about?

NCT00002392 is a clinical study titled "A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART". To ascertain the effect of thalidomide on immune responses to vaccination with polyvalent pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients; particularly, on markers of immune activation and parameters of specific, anti-HIV cellular immunity.

What is the current status of trial NCT00002392?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants.

What conditions does trial NCT00002392 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002392?

The interventions under investigation include: Thalidomide (DRUG).

Who is sponsoring clinical trial NCT00002392?

This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002392 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.